Celldex (NASDAQ: CLDX) began Monday positive, on the appointment of Teri Lawver as Senior Vice President, Chief Commercial Officer. Lawver is an accomplished global healthcare executive with 30 years of strategic, commercial launch and operating P&L leadership across the biopharmaceutical, medical device and consumer health technology sectors.
Lawver succeeds Richard Wright, who will retire from Celldex following more than a decade of dedicated leadership and service.
“We are thrilled to welcome Teri to the Celldex leadership team,” said CEO Anthony Marucci. “Teri brings an extraordinary record of success across global biopharmaceutical and medical technology companies. Her deep experience in immunology and inflammation and track record building and scaling commercial organizations will be invaluable as we prepare for the potential launch of barzolvolimab and advance our broader pipeline.
“I also want to sincerely thank Rick for his exceptional contributions over the past 10 years. His leadership and commitment have been instrumental in positioning Celldex for our next phase of growth, and we wish him all the best in his retirement.”
Ms. Lawver brings extensive experience in immunology and inflammation, having overseen multiple first-in-class portfolio advances and blockbuster launches, including pivotal indications for REMICADE® (infliximab), STELARA® (ustekinumab), and TREMFYA® (guselkumab).”
CLDX shares took on 23 cents, or 1%, to $23.12.
